AL
Akella Lakshmi Sravanthi
About Akella Lakshmi Sravanthi
Data last updated:
Akella Lakshmi Sravanthi has 5 years in corporate governance. Holds Director role. Currently with 1 company, including Aanviksha Laboratories Private Limited. Engaged in General Business. Contributes to corporate operations. The largest current company by reported revenue is Aanviksha Laboratories Private Limited at ₹7.12 Cr (FY 2024).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Aanviksha Laboratories Private Limited U24297TG2020PTC144859 | Director | 14 Oct 2020 | 2020 | ₹7.12 Cr (FY 2024) | Active |
Previous companies
Explore Director's current and past company associations Uncover their professional journey today!
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Akella Lakshmi Sravanthi
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Akella Lakshmi Sravanthi
Akella Lakshmi Sravanthi has 5 years in corporate governance. Holds Director role. Currently with 1 company, including Aanviksha Laboratories Private Limited. Engaged in General Business. Contributes to corporate operations. The largest current company by reported revenue is Aanviksha Laboratories Private Limited at ₹7.12 Cr (FY 2024).
Akella Lakshmi Sravanthi is associated with 1 company as Director, including Aanviksha Laboratories Private Limited (₹7.12 Cr).
Akella Lakshmi Sravanthi has expertise in General Business.
Akella Lakshmi Sravanthi has 5 years in corporate governance.
By reported revenue, the largest current company of Akella Lakshmi Sravanthi is Aanviksha Laboratories Private Limited, with revenue of ₹7.12 Cr (FY 2024).
Akella Lakshmi Sravanthi currently holds positions at 1 company: Aanviksha Laboratories Private Limited (₹7.12 Cr).